Zacks: Brokerages Expect Nuvectra Corporation (NVTR) Will Post Earnings of -$1.16 Per Share

Analysts expect that Nuvectra Corporation (NASDAQ:NVTR) will report earnings per share (EPS) of ($1.16) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Nuvectra Corporation’s earnings. Nuvectra Corporation reported earnings per share of ($0.92) in the same quarter last year, which would suggest a negative year over year growth rate of 26.1%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 8th.

On average, analysts expect that Nuvectra Corporation will report full year earnings of ($4.77) per share for the current financial year. For the next fiscal year, analysts anticipate that the business will report earnings of ($4.12) per share. Zacks’ earnings per share averages are an average based on a survey of analysts that follow Nuvectra Corporation.

Nuvectra Corporation (NASDAQ:NVTR) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($1.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.07. Nuvectra Corporation had a negative return on equity of 56.68% and a negative net margin of 232.31%. The firm had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $5.96 million. During the same period in the prior year, the business posted ($0.85) earnings per share. The business’s revenue was up 188.0% compared to the same quarter last year.

NVTR has been the topic of a number of research reports. TheStreet upgraded Nuvectra Corporation from a “d” rating to a “c-” rating in a research report on Monday, June 19th. Zacks Investment Research upgraded Nuvectra Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Piper Jaffray Companies restated a “neutral” rating and set a $14.00 price objective on shares of Nuvectra Corporation in a research report on Thursday, July 6th. ValuEngine upgraded Nuvectra Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 16th. Finally, B. Riley restated a “buy” rating and set a $12.00 price objective on shares of Nuvectra Corporation in a research report on Monday, May 15th. Three equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $10.50.

TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Expect Nuvectra Corporation (NVTR) Will Post Earnings of -$1.16 Per Share” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.com-unik.info/2017/08/18/zacks-brokerages-expect-nuvectra-corporation-nvtr-will-post-earnings-of-1-16-per-share.html.

Shares of Nuvectra Corporation (NVTR) traded down 1.63% during mid-day trading on Friday, reaching $11.50. The company’s stock had a trading volume of 25,410 shares. The firm has a 50 day moving average price of $12.23 and a 200 day moving average price of $9.37. The firm’s market cap is $123.04 million. Nuvectra Corporation has a 52-week low of $4.63 and a 52-week high of $15.00.

In other news, CEO Scott F. Drees acquired 2,605 shares of Nuvectra Corporation stock in a transaction that occurred on Thursday, May 25th. The shares were acquired at an average price of $9.92 per share, for a total transaction of $25,841.60. Following the transaction, the chief executive officer now directly owns 90,041 shares of the company’s stock, valued at approximately $893,206.72. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Scott F. Drees acquired 10,000 shares of Nuvectra Corporation stock in a transaction that occurred on Friday, August 11th. The shares were purchased at an average price of $11.72 per share, for a total transaction of $117,200.00. Following the transaction, the chief executive officer now directly owns 125,180 shares in the company, valued at $1,467,109.60. The disclosure for this purchase can be found here. Insiders have purchased a total of 20,000 shares of company stock worth $220,024 in the last 90 days.

A number of large investors have recently modified their holdings of the company. Gilder Gagnon Howe & Co. LLC raised its stake in shares of Nuvectra Corporation by 12.5% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 953,431 shares of the company’s stock worth $12,662,000 after buying an additional 105,580 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Nuvectra Corporation by 3.1% in the second quarter. Dimensional Fund Advisors LP now owns 701,849 shares of the company’s stock worth $9,321,000 after buying an additional 21,140 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Nuvectra Corporation by 6.2% in the second quarter. Vanguard Group Inc. now owns 310,794 shares of the company’s stock worth $4,128,000 after buying an additional 18,081 shares in the last quarter. Hodges Capital Management Inc. raised its stake in shares of Nuvectra Corporation by 18.6% in the second quarter. Hodges Capital Management Inc. now owns 227,807 shares of the company’s stock worth $3,025,000 after buying an additional 35,706 shares in the last quarter. Finally, Essex Investment Management Co. LLC raised its stake in shares of Nuvectra Corporation by 42.1% in the second quarter. Essex Investment Management Co. LLC now owns 202,623 shares of the company’s stock worth $2,691,000 after buying an additional 60,034 shares in the last quarter. Institutional investors and hedge funds own 57.75% of the company’s stock.

About Nuvectra Corporation

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Get a free copy of the Zacks research report on Nuvectra Corporation (NVTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nuvectra Corporation (NASDAQ:NVTR)

What are top analysts saying about Nuvectra Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nuvectra Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit